Payment overview · 2025
General Payments
$536.04
8 reported records · 8 companies
Healthcare provider profile · identity verified
Jose A Torres Cintron, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PONCE, PR · NPI 1700314671
Verified facts
What the public records show
CMS Open Payments records show Jose A Torres Cintron, MD received $536.04 in general payments during 2025 across 8 reported records.
Medtronic, Inc. accounted for 27.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$145.88 | 27.2% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $132.30 | 24.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $120.16 | 22.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.65 | 8.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.59 | 4.8% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $23.00 | 4.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.40 | 4.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.06 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $536.04 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $145.88 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $132.30 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $120.16 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.65 | 1 | 2025 |
Source payment records
|
|||||
| Rezum Generator Normalized: rezum generator |
Device | Boston Scientific Corporation | $25.59 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
136 | 40 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 28 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 422 | 155 |
| Famotidine | Famotidine | 323 | 89 |
| Gabapentin | Gabapentin | 311 | 101 |
| Losartan Potassium | Losartan Potassium | 187 | 71 |
| Lisinopril | Lisinopril | 184 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 144 | 54 |
| Synthroid | Levothyroxine Sodium | 136 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 125 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 38 |
| Montelukast Sodium | Montelukast Sodium | 120 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 62 |
| Metformin Hcl | Metformin Hcl | 115 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 91 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 91 | 34 |
| Furosemide | Furosemide | 87 | 57 |
| Carvedilol | Carvedilol | 81 | 40 |
| Meloxicam | Meloxicam | 72 | 27 |
| Alendronate Sodium | Alendronate Sodium | 70 | 17 |
| Omeprazole | Omeprazole | 69 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 33 |
| Allopurinol | Allopurinol | 64 | 20 |
| Spironolactone | Spironolactone | 56 | 42 |
| Jardiance | Empagliflozin | 54 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 20 |
| Irbesartan | Irbesartan | 51 | 12 |
| Clonazepam | Clonazepam | 50 | 18 |
| Simvastatin | Simvastatin | 49 | 18 |
| Eliquis | Apixaban | 46 | 28 |
| Temazepam | Temazepam | 46 | 14 |
| Farxiga | Dapagliflozin Propanediol | 45 | 15 |
| Levofloxacin | Levofloxacin | 45 | 44 |
| Nifedipine Er | Nifedipine | 42 | 26 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 41 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 39 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 39 | 17 |
| Glimepiride | Glimepiride | 38 | 12 |
| Sertraline Hcl | Sertraline Hcl | 38 | 11 |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 36 | 15 |
| Meclizine Hcl | Meclizine Hcl | 35 | 14 |
| Trazodone Hcl | Trazodone Hcl | 35 | suppressed |
| Baclofen | Baclofen | 34 | 14 |
| Brilinta | Ticagrelor | 32 | 23 |
| Chlorthalidone | Chlorthalidone | 32 | 11 |
| Methylprednisolone | Methylprednisolone | 31 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | 17 |
| Sucralfate | Sucralfate | 31 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Celecoxib | Celecoxib | 28 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | 11 |
| Azithromycin | Azithromycin | 26 | 24 |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | 12 |
| Dexamethasone | Dexamethasone | 23 | 19 |
| Humalog | Insulin Lispro | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | 14 |
| Prednisone | Prednisone | 21 | 15 |
| Pregabalin | Pregabalin | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | 11 |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Nabumetone | Nabumetone | 20 | 11 |
| Candesartan Cilexetil | Candesartan Cilexetil | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 11 |
| Finasteride | Finasteride | 18 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 18 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Fluconazole | Fluconazole | 15 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 14 |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $536.04 · 8 records | Medtronic, Inc. | CAMZYOS, EVENITY, PROLIA, REZDIFFRA, Rezum Generator, SYMPLICITY G3, UBRELVY, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error